SCHEMBL78888

SCHEMBL78888

CCC(C(=O)O)n1cnc2ccc(Oc3cccc(F)c3)cc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.43
USP5 P45974 1/20 0.41
HIF1A Q16665 1/20 0.40
CYP2D6 P10635 1/20 0.40
GRK2 P25098 1/20 0.40
GCK P35557 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
MMP13 P45452 1/20 0.37
MCHR1 Q99705 1/20 0.37
TSHR P16473 1/20 0.37
BRAF P15056 1/20 0.37
DHODH Q02127 1/20 0.37
KCNH2 Q12809 1/20 0.37
EGFR P00533 1/20 0.37
ERBB4 Q15303 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL79350 0.88 HPGD (0.44) PPARGUSP5HIF1AGCKMEN1
SCHEMBL92916 0.84 CASP3 (0.42) PPARGHIF1A
SCHEMBL27626273 0.84 CASP3 (0.42) PPARGHIF1A
SCHEMBL78912 0.84 CASP3 (0.42) PPARGHIF1A
SCHEMBL8344225 0.83 CASP1 (0.37) PPARGHIF1ACYP2D6GRK2GCK
SCHEMBL78933 0.82 USP5 (0.41) USP5GCKTSHRBRAFDHODH
SCHEMBL79402 0.81 USP5 (0.43) USP5HIF1AMCHR1TSHRBRAF
SCHEMBL78872 0.78 FFAR1 (0.43) USP5HIF1AGCKMEN1KMT2A
SCHEMBL87330 0.78 GCK (0.48) USP5GCKMEN1KMT2ATSHR
SCHEMBL77994 0.78 GCK (0.48) USP5GCKMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129381-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-12 US disclosed
US-7553852-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-30 US disclosed
EP-1539701-A1 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-06-15 EP disclosed
US-20040072850-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-04-15 US disclosed
WO-2004002961-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072850-A1 Caspase inhibitors and uses thereof CASP1, CASP5, CASP2 PPARG 2862/4885USP5 759/4885HIF1A 766/4885
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF CASP1, CASP5, CASP3 PPARG 2591/4885USP5 590/4885HIF1A 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.